Interesting tidbit- A small number of downstream entities (based on my experience thus far) are reaching out to manufacturers who they don’t actively purchase from and are asking to establish DSCSA T2 connections.
There are some understandable business drivers as to why these companies may be doing this- especially for generic products- wanting to ensure they have connections established with alternative suppliers in case their primary source can’t meet DSCSA requirements.
But the technical and practical insights are much more intriguing. First and foremost, the fact that companies are wanting to proactively establish connections to non-active trading partners is the clearest sign to date that there is no concept of a ‘network’ in pharma serialization. If there was a true network that delivered interoperability then establishing connections with non-active partners wouldn’t even be a concern. Even more intriguing is the small number of entities I’ve seen make these requests use the serialization vendor that promotes their massive ‘network’
It will be interesting to see if this turns into a bigger trend, but, at present, I don't think this is just about the business drivers, but rather companies coming to the harsh realization that the ‘connect once’ sales promise was a complete sham and they will now have to spend even more money/time/effort to try and stay ahead of the supply-disruption curve.
https://lnkd.in/gfrxUUbH
#dscsa #gs1 #epcis #hda #pdg #serialization
